Drug Profile


Alternative Names: BN 50730; LAU 8080

Latest Information Update: 30 Aug 2004

Price : $50

At a glance

  • Originator Ipsen
  • Class
  • Mechanism of Action Free radical scavengers; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Asthma; Rheumatic disorders

Most Recent Events

  • 05 Dec 2003 Discontinued - Phase-II for Rheumatic disorders in United Kingdom (unspecified route)
  • 05 Dec 2003 Discontinued - Phase-III for Rheumatic disorders in France (unspecified route)
  • 28 Aug 2003 Discontinued - Preclinical for Arrhythmias in Turkey (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top